ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2394

Sustained Remission Improves Physical Function in RA Patients Treated with Tumor Necrosis Factor Inhibitor

Jon T. Einarsson1, Meliha C. Kapetanovic2 and Pierre Geborek3, 1Dept of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 2Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, 3Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: functional status, Health Assessment Questionnaire, physical function, remission and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches

Session Type: Abstract Submissions (ACR)

Sustained Remission Improves Physical Function In RA Patients Treated with Tumor Necrosis Factor Inhibitors

Background/Purpose

Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA) patients. Despite their limitations DAS28 remission criteria are widely used. It is not clear whether achieving remission is sufficient or weather the goal should be sustained remission. Physical function measured by health assessment questionnaire (HAQ) is a major outcome in RA. HAQ is shown to be one of the strongest predictors of long-term outcomes including quality of life, work disability and mortality. 

The purpose of this study was to investigate the physical function over a long time period in RA patients treated with Tumor Necrosis Factor inhibitors (aTNF) who achieved sustained remission (SR) compared to that of patients occasionally achieving remission (non-sustained remission, nonSR).

Methods

Anti-TNF treated RA patients included in the observational South Swedish Arthritis Group register were eligible for this study. We identified patients with DAS28<2.6 at some point and those that achieved sustained remission in consecutive visits for at least 6 months. The course of functional status was assessed using HAQ at each visit.

Results

Of 2416 patients included, 1194 (49.4%) reached DAS28 remission at some point. Of those fulfilled 382 (15.8 %) the criteria for SR with median duration of 5.25 years while 812 (33.6%) had non-sustained remission. The nonSR group had mean disease duration of 11.5 years at treatment start compared to 10.1 years in the SR group, and mean HAQ of 1.3 compared to 1.0 in the SR group. Figure1 show the mean HAQ in each year after remission start with the 95% confidence interval of mean.  In the first year the mean HAQ in the SR group was 0.48(95%CI of mean 0.026) and then continued to improve in every year for 7 years.  The HAQ is significantly lower in year 4 (0.32; 95%CI 0.050) and again in year 7 compared to year 4 (0.167; 95%CI 0.058). In the nonSR group the mean HAQ in the first year was 0.701 and did not change significantly over 8 years.

Conclusion

Physical function measured by HAQ improves in patients with established RA reaching sustained remission and continues to improve while in remission. This suggests that treatment should be aimed at maintaining sustained remission.


Disclosure:

J. T. Einarsson,
None;

M. C. Kapetanovic,
None;

P. Geborek,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-remission-improves-physical-function-in-ra-patients-treated-with-tumor-necrosis-factor-inhibitor/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology